Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial

What Was Tested

Researchers studied Glatiramer Acetate in the context of multiple sclerosis in this randomized controlled trial publication.

Estriol treatment is anti-inflammatory and neuroprotective in preclinical studies.

National Institutes of Health, National Multiple Sclerosis Society, Conrad N Hilton Foundation, Jack H Skirball Foundation, Sherak Family Foundation, and the California Community Foundation.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, women only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Glatiramer Acetate study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Glatiramer Acetate.

A placebo (an inactive look-alike) gave the Glatiramer Acetate group a baseline to be compared against.

The researchers did a randomised, double-blind, placebo-controlled phase 2 trial at 16 academic neurology centres in the USA, between June 28, 2007, and Jan 9, 2014.

Analysis was by intention to treat.

The trial is registered with ClinicalTrials.gov, number NCT00451204.

What Was Measured

PubMed files the paper under topics including Adjuvants, Immunologic, Estriol, Glatiramer Acetate and Multiple Sclerosis, Relapsing-Remitting.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glatiramer Acetate in people with multiple sclerosis.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (The Lancet. Neurology), a journal based in England.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.